Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | BAD | Q92934 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403150 | 0.85 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL3228101 | 0.84 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL28758109 | 0.84 | KDM4E (0.59) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL5736742 | 0.83 | ALDH1A1 (0.60) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL3213900 | 0.82 | HPGDS (0.54) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL22283553 | 0.82 | NPC1 (0.60) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL3222314 | 0.81 | HPGDS (0.53) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL5014336 | 0.81 | FOS (0.60) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL22573586 | 0.81 | NPC1 (0.50) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL4636265 | 0.81 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-1606289-B1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7531558-B2 | e.g. 6-(4-Fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide; vanilloid (capsaicin) receptor modulator; analgesic; chronic, neuropathic, postoperative, postrheumatoid arthritic, osteoarthritic, back, cancer, dental pain, algesia, neuralgia, migraine, neuropathies, ischaemia | GLAXO GROUP LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| US-20060148855-A1 | Carboxamide derivatives | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1606289-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004072069-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, LTC4S | SMN1; SMN2 4671/4885ALDH1A1 871/4885NPC1 1707/4885 |
| US-20060148855-A1 | Carboxamide derivatives | CNR2, CNR1, SUCNR1 | SMN1; SMN2 1722/4885ALDH1A1 1895/4885NPC1 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.